Details of the Drug

General Information of Drug (ID: DM8BG0M)

Drug Name

FP-253-GDEPT

Synonyms

FP-253; PNP-GDEPT; GDEPT (prostate cancer), Mayne; GDEPT (fludarabine phosphate, prostate cancer), CSIRO; Gene-directed enzyme prodrug therapy (prostate cancer), Mayne; OAdV gene therapy (PNP/ fludarabine phosphate), Mayne; Ovine adenovirus gene therapy (purine nucleoside phosphorylase/fludarabine phosphate), Mayne; OAdV GDEPT (E coli PNP/fludarabine phosphate, prostate cancer), Broadvector; Ovine atadenovirus GDEPT (purine nucleoside phosphorylase/fludarabine phosphate, prostate cancer), Biotech Equity Partners

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1	[1]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D01OOQ

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Schistosoma Purine nucleoside phosphorylase (sch PNP)	TTVYIH7	Q9BMI9_SCHMA	Modulator	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med. 2004 Dec;6(12):1343-57.